Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 Japanese subgroup analysis.

Norihiko Tsuchiya,Yoshiaki Yamamoto,Hirotsugu Uemura,Hiro-omi Kanayama,Masatoshi Eto,Hideaki Miyake,Thomas Powles,Mizuki Yoshida,Yuichiro Koide,Yoshiko Umeyama,Alessandra di Pietro,Yoshihiko Tomita

Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 Japanese subgroup analysis.

2021

Norihiko Tsuchiya
Yoshiaki Yamamoto
Hirotsugu Uemura
Hiro-omi Kanayama
Masatoshi Eto
Hideaki Miyake
Thomas Powles
Mizuki Yoshida
Yuichiro Koide
Yoshiko Umeyama
Alessandra di Pietro
Yoshihiko Tomita

425Background: A randomized phase III trial (JAVELIN Bladder 100; NCT02603432) to investigate avelumab (anti–PD-L1) as 1L maintenance therapy in patients with advanced UC met its primary objective,...

Keywords:

Oncology
Avelumab
Subgroup analysis
Maintenance therapy
Javelin
in patient
urothelial carcinoma
Medicine
Internal medicine
first line

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations